| ■ Brain Tumor Vaccine Shows Promise | 06.11.20 |
| A vaccine for glioma brain tumors is showing promising results, according to preliminary data from a clinical trial at the University of California, San Francisco Medical Center. These early findings from the first group of six patients showed that the vaccine vitespen (trademark name Oncophage) was associated with tumor-specific immune responses in patients with recurrent, high-grade glioma. The vaccine is derived from each patient's own tumor. "This is the first documentation of a glioma-specific immune response after vaccination with vitespen," and further research is warranted, principal investigator Dr. Andrew T. Parsa, assistant professor in the department of neurological surgery, said in a prepared statement. The findings were presented Thursday at a meeting of the Society of Neuro-Oncology. ----- HealthDay News |